Compare Crispr Therapeutics AG (CRSP) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rigetti Computing Inc — how do they compare? Crispr Therapeutics AG trades at $50.4 (market cap $4.97B), while Rigetti Computing Inc trades at $15.24 (market cap $5.35B). The key difference: Crispr Therapeutics AG and Rigetti Computing Inc are close in size by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | RGTI | |
|---|---|---|
Market Cap | $4.97B | $5.35B |
Sector | Health | Technology |
52-Week High | $76.78 | $56.34 |
52-Week Low | $44.34 | $12.72 |
Enterprise Value | $3.32B | $4.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Rigetti Computing (RGTI) trades at $15.36, down 7.13% in the last 24 hours, with a bearish technical signal but bullish oscillators. The company reported a net loss of $216.21 million in 2025, with a negative net income margin of -2,253.59%, while revenue grew to $7.09 million. Recent news highlights quantum computing interest following Quantinuum's IPO and Rigetti's infrastructure developments, including the Fab-1 facility and a 108-qubit contract.
Despite significant losses and cash burn, analyst consensus is strongly bullish with an 85.71% buy rating and a $32.67 price target, suggesting over 112% upside. Key risks include high cash burn rates, intense competition, and the long timeline to quantum advantage, requiring careful risk assessment for speculative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
